IRF unimpressed by Lundbeck and Novo

The Institute for Rational Pharmacotherapy (IRF) questions the efficacy of two newly launched drugs from Lundbeck and Novo Nordisk respectively. But the assessments are not surprising, says an analyst.

Lundbeck’s pill Selincro for the treatment of alcohol dependence did not win general reimbursement from the Danish Health and Medicines Authority last month, and according to IRF there is a very good reason for that. The efficacy is simply not good enough, says the institute.

“It is the overall assessment of the IRF that nalmefen (the active substance in Selincro, ed.) could be an option for some patients, for whom non-pharmacological efforts have shown an inadequate effect. But it should be noted that the effect of nalmefen is modest and only clinically relevant in patients with a considerable alcohol dependence,” the IRF writes.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier